We are live on ! Find out more
SFM

Sphera Funds Management Portfolio holdings

AUM $630M
1-Year Est. Return 108.65%
This Fund
S&P 500
This Quarter Est. Return
-4.24%
1 Year Est. Return
+108.65%
3 Year Est. Return
+217.64%
5 Year Est. Return
+342.91%
10 Year Est. Return
+2,254.45%
AUM
$733M
AUM Growth
+$21.5M
Cap. Flow
+$93.1M
Cap. Flow %
12.7%
Top 10 Hldgs %
32.84%
Holding
138
New
34
Increased
32
Reduced
32
Closed
20

Top Buys

Rank Stock Value
1
AVGO icon
Broadcom
AVGO
+$25.7M
2
SKYE icon
Skye Bioscience
SKYE
+$15.4M
3
ASML icon
ASML
ASML
+$9.52M
4
CRM icon
Salesforce
CRM
+$8.99M
5
BBIO icon
BridgeBio Pharma
BBIO
+$8.86M

Top Sells

Rank Stock Value
1
TEVA icon
Teva Pharmaceuticals
TEVA
+$16.9M
2
FUSN
Fusion Pharmaceuticals Inc. Common Shares
FUSN
+$9.57M
3
CAMT icon
Camtek
CAMT
+$6.97M
4
CATX icon
Perspective Therapeutics
CATX
+$6.61M
5
NVMI
Nova
NVMI
+$6.23M

Sector Composition

Rank Sector Weight
1 Healthcare 59.43%
2 Technology 17.13%
3 Communication Services 3.05%
4 Consumer Discretionary 3%
5 Utilities 0.37%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
DAWN
51
DELISTED
Day One Biopharmaceuticals
DAWN
$4.79M 0.65%
347,627
-145,000
-29% -$2.12M
CPRX
52
DELISTED
Catalyst Pharmaceutical
CPRX
$4.46M 0.61%
288,000
– –
RCKT icon
53
Rocket Pharmaceuticals
RCKT
$340M
$4.46M 0.61%
206,933
+23,211
+13% +$533K
FROG icon
54
JFrog
FROG
$9.66B
$4.43M 0.6%
117,881
-106,500
-47% -$3.9M
ETNB
55
DELISTED
89bio
ETNB
$4.22M 0.58%
526,547
+10,665
+2% +$95.2K
OTLK icon
56
Outlook Therapeutics
OTLK
$183M
$4.22M 0.58%
571,428
-1
-0% -$8
WIX icon
57
WIX.com
WIX
$2.3B
$4M 0.55%
25,177
-27,700
-52% -$3.98M
LRCX icon
58
Lam Research
LRCX
$367B
$3.94M 0.54%
+37,000
New +$3.55M
SVRA icon
59
Savara
SVRA
$1.12B
$3.88M 0.53%
+962,687
New +$4.28M
GSK icon
60
GSK
GSK
$104B
$3.85M 0.53%
100,000
– –
QCOM icon
61
Qualcomm
QCOM
$155B
$3.75M 0.51%
18,825
+3,825
+26% +$722K
ELDN icon
62
Eledon Pharmaceuticals
ELDN
$261M
$3.42M 0.47%
+1,297,021
New +$3.1M
AKRO
63
DELISTED
Akero Therapeutics
AKRO
$3.32M 0.45%
141,620
-18,825
-12% -$403K
SHLT
64
DELISTED
SHL Telemedicine Ltd American Depositary Shares
SHLT
$3.22M 0.44%
632,456
– –
APLT
65
DELISTED
Applied Therapeutics
APLT
$3.15M 0.43%
674,268
+55,239
+9% +$261K
NTLA icon
66
Intellia Therapeutics
NTLA
$1.49B
$3.12M 0.43%
+139,419
New +$3.32M
AVGO icon
67
Broadcom
AVGO
$1.85T
$3.11M 0.42%
193,600
+183,590
+1,834% +$25.7M
PRAX icon
68
CALL
Praxis Precision Medicines
PRAX
$8.58B
$3.1M 0.42%
+75,000
New +$3.54M
ADI icon
69
Analog Devices
ADI
$179B
$2.97M 0.4%
+13,000
New +$2.77M
PTCT icon
70
PTC Therapeutics
PTCT
$5.68B
$2.88M 0.39%
+94,318
New +$3.06M
VTGN icon
71
VistaGen Therapeutics
VTGN
$9.89M
$2.81M 0.38%
808,550
– –
PLRX icon
72
Pliant Therapeutics
PLRX
$64.4M
$2.78M 0.38%
258,554
– –
ALEC icon
73
Alector
ALEC
$168M
$2.77M 0.38%
610,000
+50,000
+9% +$257K
ENLT icon
74
Enlight Renewable Energy
ENLT
$11.8B
$2.74M 0.37%
169,280
– –
PMN icon
75
ProMIS Neurosciences
PMN
$123M
$2.72M 0.37%
72,569
-793
-1% -$37.1K
1 2
3
4 5

Similar funds

VIM
Vancity Investment Management Vancouver, British Columbia, Canada $629M AUM 2.49% 1-Year Est. Return
KCMH
Keywise Capital Management (HK) Hong Kong $630M AUM 81.01% 1-Year Est. Return
FCFC
First Commonwealth Financial Corp Indiana, Pennsylvania $629M AUM 20.47% 1-Year Est. Return
BI
BlueSpruce Investments Chicago, Illinois $631M AUM 11.83% 1-Year Est. Return
PWW
Pettyjohn Wood & White Lynchburg, Virginia $628M AUM 20.96% 1-Year Est. Return
TTSTC
Texas Treasury Safekeeping Trust Company Austin, Texas $628M AUM 15.58% 1-Year Est. Return
SWP
Summit Wealth Partners Orlando, Florida $632M AUM 9.71% 1-Year Est. Return
EIM
Essex Investment Management Boston, Massachusetts $632M AUM 95.36% 1-Year Est. Return

Sphera Funds Management's Q2 2024 Portfolio in Review

As of Q2 2024, Sphera Funds Management held 138 positions worth $733M, up 3% from $712M the previous quarter. Its ten largest holdings account for 33% of the portfolio.

Sphera Funds Management deployed $93.1M of net new capital in Q2 2024, opening 34 new positions and adding to 32 existing holdings. Its largest new stake was Skye Bioscience: 1,298,312 shares worth $10.4M.

By sector, the portfolio is most concentrated in Healthcare at 59% of assets, down from 65% a quarter earlier, followed by Technology and Communication Services.

On the sell side, the largest reduction was Teva Pharmaceuticals, an estimated $16.9M trimmed.

  • Sphera Funds Management's largest Q2 2024 buy was Skye Bioscience: 1,298,312 shares worth $10.4M.
  • Sphera Funds Management added most to Broadcom in Q2 2024, an estimated $25.7M increase.
  • Sphera Funds Management's biggest Q2 2024 reduction was Teva Pharmaceuticals, cutting an estimated $16.9M.
  • Sphera Funds Management fully exited Fusion Pharmaceuticals Inc. Common Shares in Q2 2024, selling an estimated $9.57M.
  • Sphera Funds Management's ten largest holdings make up 33% of its $733M portfolio in Q2 2024.
  • Sphera Funds Management opened 34 new positions and closed 20 in Q2 2024.
  • Sphera Funds Management's portfolio value rose 3% quarter-over-quarter to $733M.

Based on Sphera Funds Management's 13F filing for Q2 2024, filed 14 Aug 2024.